JPH09502434A - キニノゲナーゼ阻害剤 - Google Patents
キニノゲナーゼ阻害剤Info
- Publication number
- JPH09502434A JPH09502434A JP7508506A JP50850695A JPH09502434A JP H09502434 A JPH09502434 A JP H09502434A JP 7508506 A JP7508506 A JP 7508506A JP 50850695 A JP50850695 A JP 50850695A JP H09502434 A JPH09502434 A JP H09502434A
- Authority
- JP
- Japan
- Prior art keywords
- phe
- alkyl
- substituted
- carbon atoms
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. キニノゲナーゼを阻害するペプチドまたはペプチド類似物であって、A− B−C構造を有しており、そのとき: i) Cは、下式で表され: 式中、Yは、-H、-NO2、-CN、-CONH2、-OHまたは-NH2であり; Zは、-CH2-、-NH-、-S-または-O-であり; R1、R2、R3、R4は、-H、アルキル (炭素数1〜6)、-OH、アルコキシ、 ハライド、-SH、または-S-アルキル(炭素数1〜6)であるか、またはR1R2 、R3R4の両方または片方がカルボニル基または(炭素数3〜6の)シクロアル キル基を構成し; Dは、-NR11- (式中R11は、H、炭素数1〜6の低級アルキルまたはOHであ る);もしくはSO2、CO、CH2、OまたはSであるか;あるいは(BとCとの 間のアミド結合が-CH=CH-により置換されているときには) =CH-であり; Eは、(上記R1R2、R3R4として定義される) -CR5R6-;-NR11-(R11は上 記と同様である);O;またはSであり; Fは、不存在であるか、あるいは-CR9R10-(式中、R9およびR10は、Hまた はアルキル(炭素数1〜6)であるか、またはEが-CR5R6-であるときにはR9 およびR10は上記R1、R2、R3、R4と同様に定義される) であり; そしてさらに、アミノアシル基BのカルボニルがD、EおよびFと共に、例えば オキサゾリジン、オキサゾール、アゾール、テトラゾール、イソオキサゾリン、 オキサゾリン、チアゾリン等の複素環により置換されていてもよく; ii) どちらか一方が欠けていてもよいAおよびBは、同一または異なって、アミ ノアシル残基またはアミノアシル類似物残基であり、そして特には: Aは、 a) L-、または好ましくはD-立体配置のアミノまたはイミノ、あるいは類 似物の1つの残基であり、好ましくは、Aib;Aic;Ala;Aha;Ap a;Arg;Atc;Aze;Bta;Cdi;Cha;Cin;Cit:Cp g;α-Dhn;β-Dhn;Dpn;Glu;4-Gph;3-Gph;Har; Hch;Hci;His;Hph;Hyp;Ile;Leu;Lys;Nip; α-Nal;β-Nal;2-Pal;3-Pal;4-Pal;Phe;4-CF3- Phe;4-Cl-Phe;4-CN-Phe;4-F-Phe;3-F-Phe;2- Me-Phe;4-NO2-Phe;4-NH2-Phe;2,4-Cl2-Phe;3,4 -Cl2-Pheまたはその他の置換されたPhe;Phg;Pic;Pro;β- Pro;3-Ph-Pro;α-ホモ-Pro;Pse;Pse(OR)(式中Rは炭 素数1〜10のアルキルである);Pyr;Ser;Ser(OnBu);Tal ;Tic;α-Tna;Trp;Tyr;Tyr (Et);Valから選択され、 所望により、特には-HCO、(炭素数1から6の) 低級アルキル-アシル または(炭素数1から6の)低級アルキル-芳香族アシルから選ばれるか;(炭 素数1〜6の)低級アルキル-スルホニル;アルキル(炭素数1〜10);HO2 C(CH2)n−(式中nは1〜3である)あるいはそのエステ ルまたはアミド;アミノ−アシル;アルキルオキシカルボニル;アリールオキシ カルボニル;R−アルキルアシル (式中アルキルの炭素数は1〜10であり、か つ末端基Rはグアニジノ、アミジノ、ベンズアミジノ、グアニジノフェニルおよ びアミジノフェニルから選択される)から選ばれるか;あるいは一般的にはBo c、Z、Fmocまたはその他の保護基から選ばれ得る、N-末端基を有してい てもよく; b) 好ましくはD-立体配置を有し、そして好ましくは上記アミノ酸である1 つのアミノ酸であって、N,N-ジアルキル(炭素数1〜20)によって置換され ているか、またはN,N-[HO2C(CH2)n−]2−(式中nは1〜3)によって置換 されており; c) (Bが不存在であるとき) 次式で表される基であって: 式中、nは1〜5であり;R7は、アリール、ヘテロアリールまたはアル キル(炭素数1〜20)等の親油基であって、好ましくはNap、置換されてい るNap、シクロオクチルまたはデカヒドロナフチルであり;そしてR8はR7と 同様であって、好ましくは(置換されたフェニルを含む)フェニルまたはヘテロ アリール-であり、特にはフェニルアルキルアシル-、D-またはL-アリールまた はヘテロアリール-アラニニル(alaninyl)であり、一般的にはアリール-アミノ アルキルまたはヘテロアリール-アミノアルキルであり(ここで、「アルキル」 は炭素数1〜6であり、そしてア リールは置換されていてもよい); Bは、D-または好ましくはL-立体配置の親油性アミノ酸または類似物の1 つの残基であって、所望によりそのβ-窒素部位でアルキル(炭素数1〜6)に より置換されるが、R1、R2、R3、R4、R5、R6、R9、R10が全てHである ときにはプロリンまたはプロリン類似物ではなく、特には、Ada;Aha;C ha;α-Dhn;β-Dhn;ホモ-α-Dhn;Hch;Leu;α-Nal: β-Nal;ホモ-α-Nal;Nse;Phe;4-F-Phe;5-F-Phe; Ser(OnBu);Ser(OBn);ホモ-α-Traから選択されるが、これら の芳香族アミノ酸はその環においてさらに置換されていてもよく; iii) さらに: AとBとの間、または(DがNHであるときには)BとCとの間、あるいは両方 に存在するアミド官能基-CONH-は、-CH=CH-;-CF=CH-;-CH2NR12 -(式中、R12はH、アルキルまたはOHである);-COCH2-;-CH(OH) CH2-;-CH2O-;-CH2S-;-CH2SOx- (式中xは1または2である);- NH CO-;-CH2CH2−;あるいは(D、E、Fも包含され得るときには) Cに定義された如き複素環、を包含する擬態物によって置換されることができ; 特に断らない限り「アルキル」という術語は、直鎖、分枝および環を包含してい る。 2. 前記Cが、アグマチン残基またはノルアグマチン残基である、請求項1に 記載のペプチドまたはペプチド類似物。 3. 前記Cが、置換されている、好ましくはアルキルで置換されているアグマ チン残基またはノルアグマチン残基である、請求項1に記載のペプチドまたはペ プチド類似物。 4. 請求項1、2または3のいずれかに記載のペプチドまたはペプチド類似物 を、キニノゲナーゼを阻害する量含有する、医薬学的製剤。 5. 本明細書に記載した如き状態の(予防的治療を含む)治療方法、またはそ のような治療のための、請求項1または2に記載のキニノゲナーゼを阻害する有 効量のペプチドまたはペプチド類似物を用いた、医薬の調製方法。 6. 下式: 式中、DはNR11であり、E、F、R1〜R4、ZおよびYは請求項1の定義と同 様である)で表される化合物およびその保護された形態、特には、炭素鎖が置換 されている、好ましくはアルキルで置換されている化合物であって、単純にΩ− アミノアルキルグアニジンである化合物ではない化合物。 7. 医薬学的に活性な化合物、特にはキニノゲナーゼまたはその他のセリンプ ロテイナーゼ阻害剤の合成における出発物質としての請求項6に記載の化合物の 使用。 8. 医薬学的に活性な化合物、特にはキニノゲナーゼまたはその他のセリンプ ロテイナーゼ阻害剤の構成要素としての、請求項6に記載の構造式の残基であっ て、Dに結合する水素を欠くか、またはその水素の位置にカルボニル基を有する か、あるいはDおよびそのようなカルボニル基から形成されるアミド基の位置に アミド基の構造的擬態物を有する (この場合にはΩ−アミノアルキルグアニジン の除外を適用しない)、請求項6に記載の構造式の残基。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939318637A GB9318637D0 (en) | 1993-09-08 | 1993-09-08 | Enzyme inhibitors |
GB9318637.7 | 1993-09-08 | ||
PCT/GB1994/001887 WO1995007291A1 (en) | 1993-09-08 | 1994-08-31 | Kininogen inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007252475A Division JP2008056684A (ja) | 1993-09-08 | 2007-09-27 | キニノゲナーゼ阻害剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09502434A true JPH09502434A (ja) | 1997-03-11 |
Family
ID=10741715
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7508506A Pending JPH09502434A (ja) | 1993-09-08 | 1994-08-31 | キニノゲナーゼ阻害剤 |
JP2007252475A Pending JP2008056684A (ja) | 1993-09-08 | 2007-09-27 | キニノゲナーゼ阻害剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007252475A Pending JP2008056684A (ja) | 1993-09-08 | 2007-09-27 | キニノゲナーゼ阻害剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6096712A (ja) |
EP (1) | EP0736036B1 (ja) |
JP (2) | JPH09502434A (ja) |
AT (1) | ATE279432T1 (ja) |
AU (1) | AU7505294A (ja) |
CA (1) | CA2170896A1 (ja) |
DE (1) | DE69434070T2 (ja) |
FI (1) | FI961044A (ja) |
GB (1) | GB9318637D0 (ja) |
NO (1) | NO317089B1 (ja) |
TW (1) | TW492954B (ja) |
WO (1) | WO1995007291A1 (ja) |
ZA (1) | ZA946872B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008056684A (ja) * | 1993-09-08 | 2008-03-13 | Ferring Bv | キニノゲナーゼ阻害剤 |
JPWO2014104272A1 (ja) * | 2012-12-28 | 2017-01-19 | 日本臓器製薬株式会社 | ケイ皮酸アミド誘導体 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7472896A (en) * | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
US6458806B1 (en) | 1996-08-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Aryl alkenamides derivatives as MCP-1 antagonists |
TW499412B (en) | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
JP2001524467A (ja) | 1997-11-26 | 2001-12-04 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールアミノグアニジンおよびアルコキシグアニジンおよびプロテアーゼインヒビターとしてのこれらの使用 |
US6344486B1 (en) | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
JP2003529528A (ja) * | 1998-04-24 | 2003-10-07 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | プロテアーゼインヒビターとしてのアミノ酸アミジノヒドラゾン、アルコキシグアニジン、およびアミノグアニジン |
AU759427B2 (en) | 1998-06-11 | 2003-04-17 | 3-Dimensional Pharmaceuticals, Inc. | Pyrazinone protease inhibitors |
KR100699404B1 (ko) * | 1999-02-18 | 2007-03-23 | 가켄 세야쿠 가부시키가이샤 | 성장 호르몬 분비촉진제로서의 신규 아미드 유도체 |
MXPA01011956A (es) | 1999-05-27 | 2002-06-21 | Dimensional Pharm Inc | Oxazaheterociclos como inhibidores de proteasas. |
WO2001004117A1 (en) | 1999-07-09 | 2001-01-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl protease inhibitors and diagnostic imaging agents |
MXPA03000512A (es) | 2000-07-17 | 2003-10-06 | Dimensional Pharm Inc | Oxiguanidina-pirazinonas ciclicas como inhibidores de proteasas. |
WO2002012207A1 (en) | 2000-08-04 | 2002-02-14 | 3-Dimensional Pharmaceuticals, Inc. | Cyclic oxyguanidine protease inhibitors |
DE60131032T2 (de) * | 2000-08-25 | 2008-08-14 | Research Corp. Technologies, Inc., Tucson | Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne |
GB0205527D0 (en) * | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
JP4775259B2 (ja) | 2004-03-31 | 2011-09-21 | 味の素株式会社 | アニリン誘導体 |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU178398B (en) * | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
US4568636A (en) * | 1981-03-25 | 1986-02-04 | Pentapharm Ag | Tripeptide derivatives |
US4395401A (en) * | 1981-09-09 | 1983-07-26 | Smithkline Beckman Corporation | Renally active dipeptides |
DE3505555A1 (de) * | 1985-02-18 | 1986-09-11 | Behringwerke Ag, 3550 Marburg | Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel |
DE3606480A1 (de) * | 1986-02-28 | 1987-09-03 | Behringwerke Ag | Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung |
GB9019558D0 (en) * | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
GB9024129D0 (en) * | 1990-11-06 | 1990-12-19 | Thrombosis Research Trust | Inhibitors and substrates of thrombin |
EP0617705B1 (en) * | 1991-11-22 | 1997-09-24 | Yeda Research And Development Company, Ltd. | Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them |
SE9103612D0 (sv) * | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
GB9318637D0 (en) * | 1993-09-08 | 1993-10-27 | Ferring Res Ltd | Enzyme inhibitors |
-
1993
- 1993-09-08 GB GB939318637A patent/GB9318637D0/en active Pending
-
1994
- 1994-08-31 CA CA002170896A patent/CA2170896A1/en not_active Abandoned
- 1994-08-31 AT AT94924950T patent/ATE279432T1/de not_active IP Right Cessation
- 1994-08-31 JP JP7508506A patent/JPH09502434A/ja active Pending
- 1994-08-31 EP EP94924950A patent/EP0736036B1/en not_active Expired - Lifetime
- 1994-08-31 WO PCT/GB1994/001887 patent/WO1995007291A1/en active IP Right Grant
- 1994-08-31 AU AU75052/94A patent/AU7505294A/en not_active Abandoned
- 1994-08-31 DE DE69434070T patent/DE69434070T2/de not_active Expired - Lifetime
- 1994-09-07 ZA ZA946872A patent/ZA946872B/xx unknown
- 1994-09-08 TW TW083108389A patent/TW492954B/zh not_active IP Right Cessation
-
1996
- 1996-03-06 FI FI961044A patent/FI961044A/fi not_active Application Discontinuation
- 1996-03-07 NO NO960939A patent/NO317089B1/no not_active IP Right Cessation
- 1996-05-16 US US08/605,046 patent/US6096712A/en not_active Expired - Lifetime
-
2007
- 2007-09-27 JP JP2007252475A patent/JP2008056684A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008056684A (ja) * | 1993-09-08 | 2008-03-13 | Ferring Bv | キニノゲナーゼ阻害剤 |
JPWO2014104272A1 (ja) * | 2012-12-28 | 2017-01-19 | 日本臓器製薬株式会社 | ケイ皮酸アミド誘導体 |
Also Published As
Publication number | Publication date |
---|---|
US6096712A (en) | 2000-08-01 |
DE69434070D1 (de) | 2004-11-18 |
TW492954B (en) | 2002-07-01 |
NO960939D0 (no) | 1996-03-07 |
EP0736036B1 (en) | 2004-10-13 |
ZA946872B (en) | 1995-06-30 |
JP2008056684A (ja) | 2008-03-13 |
NO960939L (no) | 1996-03-07 |
AU7505294A (en) | 1995-03-27 |
FI961044A0 (fi) | 1996-03-06 |
CA2170896A1 (en) | 1995-03-16 |
GB9318637D0 (en) | 1993-10-27 |
FI961044A (fi) | 1996-05-08 |
DE69434070T2 (de) | 2006-02-23 |
NO317089B1 (no) | 2004-08-02 |
EP0736036A1 (en) | 1996-10-09 |
WO1995007291A1 (en) | 1995-03-16 |
ATE279432T1 (de) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502434A (ja) | キニノゲナーゼ阻害剤 | |
US7183252B2 (en) | Indole peptidomimetics as thrombin receptor antagonists | |
JP3023019B2 (ja) | 抗トロンビン性トリペプチド | |
EP0272671B1 (en) | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | |
JP2755351B2 (ja) | 抗―凝集ペプチド | |
AU8438791A (en) | Kininogenase inhibitors | |
CA2246758C (en) | Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii | |
JPH09512806A (ja) | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物(ii) | |
JPH02264795A (ja) | グリシン誘導体 | |
CZ38094A3 (en) | Novel isosteric peptides | |
KR20020040787A (ko) | 디펩티딜 펩티다제 ⅳ의 국소용 신규 효능제 | |
EP0570507A1 (en) | Anti-aggregatory peptides containing an aromatic ester or amide | |
JPS62207251A (ja) | オリゴペプチジルニトリル誘導体 | |
US20060009396A1 (en) | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | |
US5521158A (en) | Pseudopeptide bradykinin receptor antagonists | |
EP0804465B1 (en) | Novel elastase inhibitors | |
WO1993011154A1 (en) | Inhibitors of the conversion of big endothelin to endothelin | |
US3850904A (en) | Psychopharmacologically active d-glu or d-his containing peptides | |
CA2272095A1 (en) | Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties | |
JPH06503315A (ja) | シクロヘキシルスタチン型のレニン−抑制性ペプチド類、それらの製造方法および薬品中におけるそれらの使用 | |
JP2017518290A (ja) | β−アレスチンエフェクターの合成 | |
KR870000371B1 (ko) | 폴리펩타이드 유도체의 제조방법 | |
JPH07316193A (ja) | ペプチド誘導体およびその用途 | |
HU184720B (en) | Process for the preparation of beta-liptropine hormone fragment peptide derivatives and pharmaceutical compositions containing said compounds as active engredient | |
CA2412954A1 (en) | Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070403 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070829 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070927 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070927 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071220 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080227 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080304 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080305 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081009 |